PTGS2 and prostate carcinoma: COX-2 expression was elevated in human colorectal adenocarcinoma and other tumors, including breast cancer, cervical cancer, prostate cancer, and lung cancer, etc. Genetic knock-out or pharmacological inhibition of COX-2 has been shown to protect against experimentally-induced carcinogenesis [45].